2,023 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Net Worth Advisory Group

Net Worth Advisory Group bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 2,023 shares of the medical research company’s stock, valued at approximately $652,000.

Several other institutional investors also recently made changes to their positions in AMGN. Vanguard Group Inc. boosted its holdings in Amgen by 6.2% during the first quarter. Vanguard Group Inc. now owns 52,088,210 shares of the medical research company’s stock worth $14,809,720,000 after buying an additional 3,045,657 shares in the last quarter. Capital International Investors boosted its stake in shares of Amgen by 547.8% during the 1st quarter. Capital International Investors now owns 7,005,269 shares of the medical research company’s stock worth $1,991,738,000 after purchasing an additional 5,923,915 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Amgen by 6.4% in the second quarter. Dimensional Fund Advisors LP now owns 2,701,631 shares of the medical research company’s stock valued at $844,137,000 after buying an additional 162,223 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Amgen by 137.1% in the first quarter. Janus Henderson Group PLC now owns 2,381,133 shares of the medical research company’s stock valued at $676,984,000 after buying an additional 1,377,007 shares during the last quarter. Finally, Boston Partners lifted its stake in shares of Amgen by 27.4% during the first quarter. Boston Partners now owns 2,237,334 shares of the medical research company’s stock valued at $635,179,000 after buying an additional 481,214 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Performance

Amgen stock opened at $321.66 on Friday. The firm’s fifty day moving average price is $326.07 and its 200 day moving average price is $312.15. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The company has a market capitalization of $172.55 billion, a price-to-earnings ratio of 45.95, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. Amgen Inc. has a 12-month low of $249.70 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. During the same period in the prior year, the company posted $5.00 EPS. The company’s revenue for the quarter was up 20.1% on a year-over-year basis. On average, research analysts forecast that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.80%. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Dbs Bank raised Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 price target (up from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $362.00 price objective on shares of Amgen in a research note on Thursday, September 26th. Sanford C. Bernstein assumed coverage on shares of Amgen in a research report on Thursday. They issued an “outperform” rating and a $380.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on shares of Amgen in a report on Friday, September 27th. They issued an “overweight” rating and a $405.00 target price for the company. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus target price of $329.48.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.